Jaguar Gene Therapy
Keñya Edmondson has an extensive work experience in the pharmaceutical industry. In 2009, they joined Pfizer Pharmaceuticals as a Senior Director, overseeing Parenterals Operations. After almost a decade in this role, they transitioned to Novartis Gene Therapies in 2018, serving as the Vice President of External Manufacturing & Strategic Sourcing. In 2021, Keñya joined Jaguar Gene Therapy as the Vice President of Program Management & Strategy. Currently, they are working at Pfizer as the Vice President of Sterile Injectables Operations, a position they assumed in 2022.
Keñya Edmondson obtained a Bachelor's degree in Pre-Med Biology from Hampton University, starting in 1988 and completing in 1991. Subsequently, they pursued a Master's degree in Industrial Pharmacy at Long Island University, which they accomplished between the years 1994 and 1996.
This person is not in any offices
Jaguar Gene Therapy
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by the former AveXis leadership team and backed by Deerfield Management, a healthcare-specific investment firm, Jaguar brings streamlined R&D, manufacturing and clinical operations to accelerate development and potential approval of therapies for severe genetic diseases.